Trial Profile

International, Multicenter, Randomized, Partially Blind Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efavirenz (Primary) ; Elsulfavirine (Primary) ; Emtricitabine/tenofovir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Viriom

21 Sep 2018 Status changed from active, no longer recruiting to completed.
25 Jul 2017 According to a Viriom media release, based on the data from this study, Elsulfavirine has been approved for the treatment of HIV-1 infection in Russia.
12 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com